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We examined the effect of
radiation therapy (RT) on the
ability of cathepsin-activated
fluorescent probes to detect
soft tissue sarcoma (STS) in
mice. Using a primary mouse
model of STS, we showed
that RT does not compromise
probe activation or cathepsin
expression in the tumor.
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Open access undePurpose: Cathepsin-activated fluorescent probes can detect tumors in mice and in canine patients.
We previously showed that these probes can detect microscopic residual sarcoma in the tumor bed
of mice during gross total resection. Many patients with soft tissue sarcoma (STS) and other
tumors undergo radiation therapy (RT) before surgery. This study assesses the effect of RT on
the ability of cathepsin-activated probes to differentiate between normal and cancerous tissue.
Methods and Materials: A genetically engineered mouse model of STS was used to generate
primary hind limb sarcomas that were treated with hypofractionated RT. Mice were injected intrave-
nously with cathepsin-activated fluorescent probes, and various tissues, including the tumor, were
imagedusing ahand-held imagingdevice.Resected tumor andnormalmuscle sampleswere harvested
to assess cathepsin expression byWestern blot. Uptake of activated probewas analyzed by flow cyto-
metry and confocal microscopy. Parallel in vitro studies using mouse sarcoma cells were performed.
Results: RTof primary STS in mice and mouse sarcoma cell lines caused no change in probe activa-
tion or cathepsin protease expression. Increasing radiation dose resulted in an upward trend in probe
activation. Flow cytometry and immunofluorescence showed that a substantial proportion of probe-
labeled cells were CD11b-positive tumor-associated immune cells.
Conclusions: In this primarymurinemodelof STS,RTdid not affect the ability of cathepsin-activated
probes to differentiate between tumor and normal muscle. Cathepsin-activated probes labeled tumor
cells and tumor-associated macrophages. Our results suggest that it would be feasible to include
patients who have received preoperative RT in clinical studies evaluating cathepsin-activated imaging
probes.
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Soft tissue sarcoma (STS) of the extremity is commonly treated
with limb-sparing surgery. In these patients, the use of adjuvant
radiation therapy (RT) improves local control from approximately
66% to 90% (1-3). Compared with postoperative RT, preoperative
RT is associated with increased rates of wound complications but
less subcutaneous fibrosis, joint stiffness, and edema, with no
significant change in local control or survival (4, 5). Therefore,
preoperative RT is often used to treat patients with a high-grade
STS of the extremity.
When a sarcoma is resected, a pathologist examines the resected
tumor and determines whether cancer is present at the inked
surgical margin. If tumor cells extend to the edge of the specimen,
the margin is considered positive. A positive margin is associated
with increased rates of local recurrence and reoperation (6). This
method is prone to sampling error, as only a small fraction of the
resected tumor is inspected. Furthermore, because the tumor bed is
not examined, this method may miss skip lesions or tumor cells that
have contaminated the tumor bed during surgery.
A wide field-of-view imaging system has been developed to
detect microscopic residual cancer in a surgical tumor bed using
a hand-held device that detects near-infrared (NIR) fluorescence
(7). The imaging device has a spatial resolution of approximately
16 mm and a field of view of 9.0  6.6 mm, allowing one to scan
a tumor bed quickly. The system has been optimized to detect NIR
light, allowing for relatively increased tissue penetration. Prosense
680 and VM249 are cathepsin-activated fluorescent probes that
emit a NIR signal when their peptide backbone is cleaved by
cysteine proteases including cathepsins B and L. By using the
hand-held imaging device, small clusters of cells that have acti-
vated VM249 or Prosense 680 can be detected in a tumor bed after
surgical resection (7).
Because cathepsin proteases are preferentially expressed in STS
compared to adjacent skeletal muscle (7), a cathepsin-activated
fluorescent probe can provide signal contrast between the normal
tissue and tumor. Preclinical studies have shown that this imaging
system can detect cancer in a primary murine model of STS (7) and
spontaneous cancers in canine patients (8). In the murine sarcoma
model (9), the presence of NIR signal in the tumor bed correlates
with microscopic residual sarcoma and local recurrence. Further-
more, the removal of tissue with residual fluorescence improves
local control (7). Therefore, if this imaging technology can be
successfully translated in human clinical trials, it has the potential
to risk-stratify patients for local recurrence and improve outcomes.
A phase 1 clinical trial is now underway to test the safety of
a cathepsin-activated fluorescent probe in patients with STS
(NCT01626066). To determine whether patients receiving preop-
erative RT should be included in the clinical trial, we performed
preclinical studies to understand the effect of radiation on the
expression of cathepsin proteases, the activation of cathepsin-
activated probes, and imaging of primary STS in mice.Methods and Materials
Murine model and irradiation technique
All animal studies were performed in accordance with Institutional
Animal Care and Use Committee (IACUC)-approved protocols.
We used genetically engineered BrafCA; p53Fl/Fl or LSL-KrasG12D;p53Fl/Fl mice to generate primary STS as previously described (9).
Once tumors were approximately 5 to 10 mm in greatest dimen-
sion, the mice were treated with RT to the involved hind limb.
Radiation was administered in 5-Gy daily fractions to a total dose
of 0, 5, 15, or 25 Gy using a single field from a XRAD 320 Bio-
logical Irradiator (Precision X-ray, North Branford, CT) at a dose
rate of 2 to 2.2 Gy/min with 320 kVp photons at 12.5 mA using
a 2.5-mm Al/0.1-mm Cu filter. Three orthogonal tumor dimensions
were measured at regular intervals, and volumes were calculated
using the following equation: Volume Z p/6 (Dimension 1 *
Dimension 2 * Dimension 3). Tumor volumewas compared among
groups using the Student t test.
Imaging
One week after finishing RT, mice were administered 2 nmol of
VM249 (PerkinElmer, San Jose, CA) in 100 mL of phosphate-
buffered saline (PBS) via tail vein injection. Six hours after
injection, the mice were killed and the STS were resected. The
surgical margin was inked, and muscle from the contralateral hind
limb was harvested. The tumor, contralateral muscle, and tumor
bed were imaged using the hand-held imaging device (Lumicell
Diagnostics, Waltham, MA). Images were analyzed as previously
described (7). The mean signal intensity was also calculated to
determine the tumor:muscle signal ratio and the tumor:tumor bed
signal ratio for each group (nZ4-5). In addition, the inked tumor
margin from the resected specimen was subjected to conventional
histopathological analysis.
Western blot analysis
Protein isolated from tissue or cell lines was resolved on a sodium
dodecyl sulfateepolyacrylamide gel electrophoresis (SDS-PAGE)
gel (Biorad Laboratories, Hercules, CA), and membranes were
probed with anti-Cathepsin B (sc-6493) and L (sc-6501) anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-
GAPDH antibody (G9545, Sigma-Aldrich, St. Louis, MO) was
used as a loading control.
Imaging of individual cells placed over a simulated
tumor bed
Mice bearing primary STS were injected with 2 nmol of Pros-
ense 680 (PerkinElmer, San Jose, CA) via tail vein injection.
The sarcoma was resected 24 hours later, and the tumor was
homogenized and passed through a strainer to separate the
tumor aggregate into individual cells. Single cells were sorted
for Prosense (þ) signal using flow cytometry (FACSVantage;
Becton Dickinson, Franklin Lakes, NJ) and single cell suspen-
sions were stored in PBS on ice. Within 2 hours, a simulated
tumor bed was generated in recipient mice with or without prior
Prosense 680 injection by exposing the gluteal muscle with
a scalpel. A 50-mL quantity of the cell suspension was deposited
over the exposed muscle tissue, while the area was imaged with
the device. For confocal imaging (Leica SP5 Confocal Micro-
scope; Wetzlar, Germany), normal muscle tissue was removed
from tumor-free mice 24 hours after Prosense 680 injection and
placed over a microscope slide, and 50 mL of the cell suspension
was placed on top. Confocal images were taken at 20 and 63
magnification.
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Frozen sections 5 to 20 mm thick were blocked with serum and
incubated with an anti-F4/80 antibody (14-4801, eBioscience, San
Diego, CA) followed by an Alexa Fluor 488 labeled secondary
antibody (A-21208; Invitrogen, Grand Island, NY). Nuclei were
stained with 40,6-diamidino-2-phenylindole (DAPI), and slides
were imaged by confocal microscopy.
Total body irradiation and VM249 activation in
normal tissues
Non-tumor-bearing LSL-KrasG12D;p53Fl/Fl mice were treated with
total body irradiation (TBI) at a dose of 720 cGy in 4 daily 180-
cGy fractions using the 320 kVp x-ray source described above.
One week later, irradiated and nonirradiated mice were intrave-
nously injected with 2 nmol VM249 and sacrificed 6 hours later.
Muscle, liver, small bowel, stomach, lung, kidney, and spleen
were removed, washed in PBS, and imaged using the device. The
mean signal intensity for each sample was obtained as described
previously (7).
In vitro studies
Cells from a primary mouse STS were harvested from a BrafCA
;p53Fl/Fl mouse and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum. Sarcoma cells
were plated in equal density, grown to 70% to 80% confluency,
and irradiated with 0, 2, 4, or 6 Gy using the 320-kVp x-ray sourceFig. 1. Radiation therapy (RT) causes growth delay in primary soft t
Schematic depiction of method using genetically engineered mice for g
subsequent imaging of the tumor and related tissue. (B) Absolute chanat a dose rate of 2.2 Gy/min. Twenty-four hours later, VM249 was
added at a concentration of 0 nmol/L, 500 nmol/L, or 1500 nmol/
L. Forty-eight hours after radiation cells were harvested, washed
in PBS, and resuspended with propidium iodide in PBS. Cells
were analyzed and counted by flow cytometry. Scatter plots were
gated and analyzed using FlowJo Software (Ashland, OR).
Results
RT does not compromise NIR signal in a murine
model of STS
BrafCA;p53Fl/Fl mice were used to generate primary hind limb STS
expressing BrafV600E with p53 deletion (7). These mice were
randomized to treatment with 0, 5, 15, or 25 Gy in 5-Gy daily
fractions, and tumor volume was measured every 2 to 3 days
(Fig. 1A). At 7 days after completion of RT, mice treated with 15
or 25 Gy showed significant tumor growth delay compared with
mice treated with a single 5-Gy fraction (P<.05, Fig. 1B, C). At
day 5 for untreated mice and day 7 for irradiated mice, mice were
injected with the cathepsin-activated fluorescent probe VM249
and sacrificed 6 hours later. The resected tumor, tumor bed, and
contralateral hind limb muscle were then imaged using the hand-
held device (Fig. 2A, B). The use of RT did not significantly affect
the tumor:muscle signal ratio (P<.173, control compared to 25
Gy), but there was a trend toward a higher tumor:muscle ratio with
increasing radiation dose (Fig. 2C). The tumor:tumor bed signal
ratio was not significantly different for untreated mice or mice
treated with 15 or 25 Gy with a histopathologically confirmed
negative surgical margin (Fig. 2D).issue sarcoma (STS) of the hindlimb in BrafCA; p53Fl/Fl mice. (A)
eneration of primary hind limb sarcomas, treatment with RT, and
ge and (C) fold change in tumor volume after RT.
Fig. 2. Radiation therapy does not affect relative imaging signal intensity. VM249 was administered to mice from Fig. 1 and the near-
infrared fluorescent signal from the imaged tissue is represented qualitatively (A) and quantitatively (B) (exposureZ 5 ms). Fluorescence
histograms were used to calculate the mean fluorescence intensity for each imaged tissue to determine signal ratios. (C) Tumor:normal muscle
signal ratio for mice with and without RT. (D) Tumor:tumor bed signal ratio for those tumors with a histologically negative surgical margin.
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activation after RT
Western blot analysis of fresh tissue from mice with and without
RT showed that Cathepsin B and L were strongly expressed in the
tumor but not the muscle, and levels of expression did not change
with RT (Fig. 3A).
To study the effect of RT on cathepsin expression in vitro,
murine STS cells were irradiated with 0, 2, 4, or 6 Gy in a single
fraction. Cells were harvested 24 hours later and analyzed by
Western blot (Fig. 3B). Cathepsin B and L were strongly
expressed in tumor cell lines, and expression levels did not
significantly vary with increasing radiation dose.
In vitro probe activation was assessed by incubating radiation
treated cells with VM249. Cells were harvested, and flow
cytometry was used to quantify the percentage of viable cells
labeled with VM249. RT resulted in a small (w2%/Gy), increase
in labeling of cells by VM249 (Fig. 3C).Cathepsin-activated probes label tumor
parenchymal and immune cells
We examined the in vivo localization of activated probe in the tumor
bed and in individual cells. Cells were harvested from a sarcoma in
amouse after injection of Prosense 680 (Fig. 4A). Prosense(þ) cellswere isolated and reintroduced into a simulated mouse tumor bed,
where they were imaged with the hand-held device (Fig. 4B-E).
Prosense(þ) cells were also imaged using confocal microscopy,
revealing a punctuate cytosplasmic distribution, localizing Pros-
ense 680 within organelles, such as lysosomes (Fig. 4F).
We then studied probe activation within the native tumor
environment by preparing frozen sections of primary STS from
irradiated and nonirradiated mice after injection of VM249.
Fluorescence microscopy of these samples demonstrates both
VM249-positive tumor cells and VM249-positive F4/80-stained
macrophages (Fig. 5A). VM249 activation by both cell types is
maintained in mice that received RT (Fig. 5B).
In a separate experiment, STS were generated in Rosa26YFP/YFP;
LSL-KrasG12D; p53Fl/Fl mice. These sarcoma cells express the
yellow fluorescent protein (YFP). Micewith STSwere injected with
Prosense 680. Cells were isolated from the tumors of 5 mice and
analyzed by flow cytometry. Of the Prosense(þ) cells, 59.2 6.1%
were YFP(þ) tumor parenchymal cells and 29.6  9.1% were
positive for CD11b, a marker of tumor associated macrophages
(TAM) (Fig. 5D). Together, these results suggest that both sarcoma
cells and TAMs are labeled by the cathepsin-activated probes.
Effects of RT on VM249 activation in organs
Non-tumor-bearing mice were treated with total body irradiation
and injected with VM249. The heart, kidney, liver, lung, spleen,
Fig. 3. Irradiation does not alter cathepsin expression or probe
activation. (A) Representative cathepsin protein levels found in
sarcoma and normal muscle harvested from mice that received 0,
5, 15 or 25 Gy (nZ2 per radiation treatment [RT] group). (B)
Cathepsin protein levels representative of 3 sarcoma cell lines
treated with 0, 2, 4, or 6 Gy. (C) Flow-cytometric analysis showing
the effect of RT on labeling of sarcoma cells by 500 nmol/L or
1500 nmol/L VM249.
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held imaging device. RT did not significantly alter the amount of
signal from VM249 in each organ imaged (Fig. 6). High levels ofFig. 4. Imaging individual cells transferred into simulated tumor
a sarcoma-bearing mouse 24 hours after Prosense 680 injection. Individu
held imaging device when placed in a simulated tumor bed from a mous
signal was confirmed to originate from individual cells by confocal micro
(middle, blue), which were merged together (bottom). Insets in B and C
bars Z 5 mm for B and C, and 10 mm for F.signal were seen in the kidney, which excretes the probe. Skeletal
muscle and cardiac muscle demonstrated similar signal intensities.
Discussion
Given the high expression of cathepsin proteases in sarcomas
compared with skeletal muscle, cathepsin-activated fluorescent
probes are promising agents for intraoperative imaging of STS.
We have shown that these probes can be used during surgery in
sarcoma-bearing mice, to detect residual fluorescence in the tumor
bed that correlates with residual cancer cells and local recurrence
(7). Based on these results and a clinical trial testing this tech-
nology in canine patients with spontaneous tumors (8), a phase 1
clinical trial is now open to test the safety of a cathepsin-activated
fluorescent probe in humans with STS or breast cancer
(NCT01626066).
The utility of cathepsin-activated probes to discriminate
between tumor and normal tissue has also been shown in other
types of cancer. Eser et al used a murine model of pancreatic
ductal adenocarcinoma to show that a cathepsin-activated NIR
probe could detect low-grade lesions and could differentiate tumor
from normal tissue (10). In addition, topically applied cathepsin-
based probes have been used ex vivo to label human high-grade
glioma specimens (11). Furthermore, 5-ALA fluorescence has
been shown to complement intraoperative magnetic resonance
imaging in glioma patients and to significantly improve the extent
of resection (12).
There are few reports on the effect of RT on cathepsin protease
expression and activity. Seo et al studied the effects of radiation on
cathepsin S expression in a breast cancer model, finding that RT
transiently induced cathepsin S expression (13). In the current
study, cathepsins B and L were expressed at much higher levels in
resected mouse sarcoma compared with skeletal muscle or tumor
bed in vivo. Levels of cathepsins B and L remained constant with
increasing radiation dose both in vivo and in vitro. Accordingly,beds in vivo. (A) Cells were obtained by flow cytometry from
al Prosense (þ) cells from the sarcoma were detected by the hand-
e not injected (B) and injected (C) with Prosense 680. (F) Prosense
scopy in the Prosense channel (top, red) and nuclear Hoechst stain
show a 2.5 magnification of the highlighted area (D, E). Scale
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Fig. 6. Background probe activation in different tissues is not
affected by total body irradiation. Mice without tumors were
treated with TBI to 0 Gy or 7.2 Gy in 180-cGy daily fractions and
injected with VM249 1 week later. The mice were killed 6 hours
after injection, at which time individual organs were removed,
washed in phosphate-buffered saline, and imaged using the hand-
held device.
Fig. 5. Probe activation and the tumormicroenvironment. (A)Untreatedmice or (B)mice treatedwith 5Gywere injectedwithVM249 7 days
after completion ofRT. Tumorswere harvested 6 hours after probe injection, andunfixed tumor frozen sectionswere stainedwith themacrophage
marker F4/80 and nuclear stainDAPI (images are representative of 4mice per treatment group). (C) Flow cytometry plots are representative of 5
mice, showing tumor cells from sarcoma bearing Rosa26YFP/YFP; LSL-KrasG12D; p53Fl/Fl mice that were injected with Prosense 680 24 hours
before tumor harvest. (D) Staining for CD11b was used to analyze Prosense 680 labeled cells for tumor associated immune cells.
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that cathepsin activity is not modulated by radiation.
Tumor associated macrophages play an important role in the
activation of cathepsin-activated probes in this system, as
approximately 30% of the cells that activated cathepsin-based
probes were CD11b(þ). Immunofluorescence studies showed RT
independent co-localization of probe to both tumor parenchymal
and immune cells. These data suggest that RT does not reduce
probe activation by cathepsin proteases expressed by tumor
parenchyma or immune cells.
There are several limitations to our preoperative radiation
murine model. The National Comprehensive Cancer Network
(NCCN) recommends treatment in 2-Gy fractions to 50 Gy for
patients with STS receiving neoadjuvant RT (14). In the current
study, mice were treated with 5-Gy fractions from 0 to 25 Gy,
which is the equivalent 2-Gy dose (EQD2) of 40 Gy, assuming an
a/b ratio of 3. In addition, there is typically a 1-month break after
finishing RT before surgery. In this study, murine sarcomas were
resected after 1 week because of rapid tumor growth. Finally, this
murine sarcoma model is most similar to undifferentiated pleo-
morphic sarcoma compared with other STS subtypes (15), and the
treatment effect as assessed by histology appeared to be modest
with this dose and schedule of RT. It is possible that for some
subtypes of STS, such as myxoid liposarcoma, which are particu-
larly responsive to radiation (16), the effect on cathepsin-activated
probes would be more substantial.
Despite these limitations, the imaging system was effective at
differentiating tumor from muscle after RT, as neither thetumor:muscle nor the tumor:tumor bed signal ratios were
compromised. Furthermore, TBI did not significantly alter the
signal from VM249 in several types of normal tissue. In vitro,
radiation resulted in a small increase in VM249 activation in
tumor cells. Taken together, these findings indicate that the use of
Cuneo et al. International Journal of Radiation Oncology  Biology  Physics142preoperative RT does not impair the ability of cathepsin-activated
imaging probes to preferentially label sarcomas compared with
normal muscle. Therefore, this study supports the inclusion of
patients treated with preoperative RT in the phase 1 clinical trial
testing this technology.
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